about
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the fi...
Read More
4.25
-0.01
(-0.23%)
25,057
XNAS Volume
XNAS 13 Jan, 2026 4:30 PM (EST)
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution
View Similar
Embed DVM
Cellectis (ADR) Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..